Effect of GM-CSF to the M-VAC Chemotherapy Induced Leukopenia in Patients with Urothelial Cancer.
- Author:
Jong Bo CHOI
1
;
Dong Sun KIM
;
Jae Heung CHO
Author Information
1. Department of Urology, Korea University, College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
GM-CSF;
M-VAC chemotherapy
- MeSH:
Appointments and Schedules;
Colony-Stimulating Factors;
Doxorubicin;
Drug Therapy*;
Granulocyte-Macrophage Colony-Stimulating Factor*;
Granulocytes;
Humans;
Leukocyte Count;
Leukopenia*;
Sepsis;
Vinblastine
- From:Korean Journal of Urology
1994;35(2):151-155
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Granulocyte macrophage-colony stimulating factor (GM-CSF) occupies a central position in the regulation of hematopoietic responses. GM-CSF not only signals proliferations of granulocyte-macrophage but also drives these cells into differentiation and activates mature cells of the GM-CSF sensitive lineage. Myelosuppression that is induced by M-VAC (methotrexate, vinblastine, doxorubicin, cisplatinum) chemotherapy brings many problems in successful treatment such as sepsis, dose reduction, delaying the schedule. Granulocyte-macrophage colony stimulating factor is introduced hopefully as a new solution for these problems. So we evaluated the efficacy and safety of GM-CSF in leukopenia induced by M-VAC chemotherapy in patients with urothelial cancer. GM-CSF was administered at 200ug subcutaneously in 10 M-VAC cycles of 6 patients on 5th and 6th day after M-VAC therapy. Sixteen cycles, by which only M-VAC chemotherapy was administered without GM-CSF. of the other 6 patients served as control group. Mean white blood cell count in peripheral blood at M-VAC 2nd day and 15th day was 5,630/mm3 and 4,240/mm3 in GM-CSF administered cycles, 6,58l/mm3and 3,613/mm3 in non GM-CSF administered cycles. There was no delayed cycle in administration of MTX and vinblastine at M-VAC 15th day in the cycles with GM-CSF. There was no significant side effects caused by GM- CSF. The result indicates that GM-CSF can be used safely and effectively against leukopenia after M-VAC chemotherapy of urothelial cancer.
